TGTX earnings call for the period ending March 31, 2019.
News & Analysis: TG Therapeutics
The stock price of this clinical-stage biotech has nearly doubled so far in 2019.
These three biotech stocks are worth buying this month.
A string of positive news on drugs in development sparked investor excitement.
Positive data from a cohort in a key trial ignited investor optimism.
A new year and reasons to remain hopeful for these three biotechs are around the corner.
Investors hit the exits last month after TG Therapeutics missed a key clinical milestone.
These three biotechs will soon present clinical trial results that could send their share prices screaming in one direction or the other.
The company's pathway to the FDA just got a bit bumpier.
Clinical trial results and an FDA approval decision will move these three stocks in the weeks ahead.